Dose-related effects of smallpox vaccine

Sharon E. Frey  
*Saint Louis University School of Medicine*

Frances K. Newman  
*Saint Louis University School of Medicine*

John Cruz  
*University of Massachusetts Medical School*

See next page for additional authors

Follow this and additional works at: [http://escholarship.umassmed.edu/infdis_pp](http://escholarship.umassmed.edu/infdis_pp)

Part of the [Immunity Commons](http://escholarship.umassmed.edu/immunity_commons), [Immunology of Infectious Disease Commons](http://escholarship.umassmed.edu/immunology_of_infectious_disease_commons), [Immunoprophylaxis and Therapy Commons](http://escholarship.umassmed.edu/immunoprophylaxis_and_therapy_commons), and the [Infectious Disease Commons](http://escholarship.umassmed.edu/infectious_disease_commons)

Repository Citation

Frey, Sharon E.; Newman, Frances K.; Cruz, John; Shelton, W. Brian; Tennant, Janice M.; Polach, Tamara; Rothman, Alan L.; Kennedy, Jeffrey S.; Wolff, Mark; Belshe, Robert B.; and Ennis, Francis A., "Dose-related effects of smallpox vaccine" (2002). *Infectious Diseases and Immunology Publications and Presentations*. 282.  
[http://escholarship.umassmed.edu/infdis_pp/282](http://escholarship.umassmed.edu/infdis_pp/282)

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Infectious Diseases and Immunology Publications and Presentations by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Dose-related effects of smallpox vaccine

Authors

Keywords
smallpox vaccine, vaccinia virus vaccine

Rights and Permissions
Copyright © 2002 Massachusetts Medical Society. Publisher PDF posted after 6 months as allowed by the publisher’s author rights policy at http://www.nejm.org/page/author-center/permissions.
DOSE-RELATED EFFECTS OF SMALLPOX VACCINE

SHARON E. FREY, M.D., FRANCES K. NEWMAN, M.S., JOHN CRUZ, B.S., W. BRIAN SHELTON, PH.D., JANICE M. TENNANT, M.P.H., TAMARA POLACH, B.S., ALAN L. ROTHMAN, M.D., JEFFREY S. KENNEDY, M.D., MARK WOLFF, PH.D., ROBERT B. BELSHE, M.D., AND FRANCIS A. ENNIS, M.D.

ABSTRACT

Background We conducted a double-blind, randomized trial of three dilutions of vaccinia virus vaccine in previously unimmunized adults in order to assess the clinical success rates, humoral responses, and virus-specific activity of cytotoxic T cells and interferon-γ–producing T cells.

Methods Sixty healthy adults were inoculated intradermally by bifurcated needle with undiluted vaccine (dose, 10^7.8 plaque-forming units [pfu] per milliliter), a 1:10 dilution (dose, 10^6 pfu per milliliter), or a 1:100 dilution (dose, 10^5 pfu per milliliter); there were 20 subjects in each group. The subjects were monitored with respect to vesicle formation (an indicator of successful vaccination), the viral titer at the time of peak lesion formation, antiviral antibodies, and cellular immune responses.

Results A vaccinia vesicle developed in 19 of the 20 subjects who received undiluted vaccine (95 percent), 14 of the 20 who received the 1:10 dilution (70 percent), and 3 of the 20 who received the 1:100 dilution (15 percent). One month after vaccination, 34 of 36 subjects with vesicles had antibody responses, as compared with only 1 of 24 subjects without clinical evidence of vaccinia virus replication. Vigorous cytotoxic T-cell and interferon-γ responses occurred in 94 percent of subjects with vesicles, and a cytotoxic T-cell response occurred in only one subject without a vesicle.

Conclusions The vaccinia virus vaccine (which was produced in 1982 or earlier) still has substantial potency when administered by a bifurcated needle to previously unvaccinated adults. Diluting the vaccine reduces the rate of successful vaccination. The development of vesicular skin lesions after vaccination correlates with the induction of the antibody and T-cell responses that are considered essential for clearing vaccinia virus infections.

From the Department of Medicine, National Institute of Allergy and Infectious Diseases Vaccine and Treatment Evaluation Unit, Saint Louis University School of Medicine, St. Louis, Mo.; the Centers for Disease Control and Prevention (CDC) in Atlanta, contains approximately 10^8 pox-forming units per milliliter. Supplies of lyophilized vaccine in the United States consist of an estimated 15 million doses. In addition, 70 to 90 million doses of frozen liquid-formulation smallpox vaccine have been identified in long-term storage by a vaccine manufacturer (Aventis, Swiftwater, Pa.); the U.S. government is reportedly negotiating to acquire this vaccine. Efforts are under way to develop a tissue-culture–derived vaccinia virus vaccine. In the interim, we evaluated the available vaccine to determine whether dilution altered the rate of successful viral replication at the inoculation site and immune responses.

This article was published at www.nejm.org on March 28, 2002.

SMALLPOX vaccine (vaccinia virus) is highly effective in immunizing against smallpox and can prevent disease when given as late as two to three days after exposure. A comprehensive public health program coupled with vaccination enabled the World Health Assembly to declare the world free of smallpox in 1980. General use of the vaccine in the United States ended in 1972. Currently, less than half the world’s population has been exposed either to smallpox (variola virus) or to the vaccine. This fact prompted several government and world health authorities to warn about the serious threat of smallpox as a biologic weapon. The probability of a release of smallpox is not known, but the effect could be catastrophic in an unimmunized population.

The immune responses required to protect a person from smallpox after vaccination are not completely understood. Adverse events due to vaccinia in children with a T-cell deficiency and an adult with undiagnosed infection with human immunodeficiency virus type 1 (HIV-1) but not in children with agammaglobulinemia. Therefore, detailed analyses of T-cell responses in addition to antibody responses after vaccination may improve our understanding of the effects of dilution on the immunogenicity of vaccinia virus vaccine.

The last lots of vaccinia vaccine manufactured in the United States, in 1982, were produced by the classic method involving scarification of calves followed by collection of vaccinia virus from draining calf lymph. Concern about contamination with bacteria or other agents from bovines makes further use of this method unfeasible. The lyophilized vaccine, which is stored at the Centers for Disease Control and Prevention (CDC) in Atlanta, contains approximately 10^8 pox-forming units per milliliter. Supplies of lyophilized vaccine in the United States consist of an estimated 15 million doses. In addition, 70 to 90 million doses of frozen liquid-formulation smallpox vaccine have been identified in long-term storage by a vaccine manufacturer (Aventis, Swiftwater, Pa.); the U.S. government is reportedly negotiating to acquire this vaccine. Efforts are under way to develop a tissue-culture–derived vaccinia virus vaccine. In the interim, we evaluated the available vaccine to determine whether dilution altered the rate of successful viral replication at the inoculation site and immune responses.
METHODS

Vaccine

The vaccine (Dryvax, Wyeth Laboratories, Marietta, Pa.; lot no. 4998391 [titer, 10⁷ plaque-forming units, or pfu, per milliliter] and lot no. 4008257 [titer, 10⁹ pfu per milliliter]) and diluent were provided by the CDC. The vaccine is a lyophilized product prepared from calf lymph. The diluent contains 50 percent glyc- erin, 0.25 percent ethanol, and 0.005 percent brilliant green dye in water. The vaccine was reconstituted on the day of administration according to the package insert. The undiluted vaccine was se- rally diluted with diluent. Coded vials were stored at 4°C until use. Because the vaccine was highly viscous and difficult to manipulate, viral titers were determined in each of the 19 vials prepared, as de- scribed previously.¹⁰ Titors are expressed as the number of plaque- forming units per milliliter.

Study Design and Subjects

The study was a randomized, double-blind trial conducted at the National Institute of Allergy and Infectious Diseases Vaccine and Treatment Evaluation Unit in St. Louis. The protocol was ap- proved by the institutional review board of Saint Louis University. All subjects provided written informed consent and were enrolled between April 2000 and October 2000. Long-term follow-up to assess the duration of immune responses is ongoing.

Healthy adults 18 to 30 years of age were eligible if they had no vaccination scar; no history of vaccinia virus vaccination; normal re- nal and hepatic serum chemical values; negative tests for hepatitis B surface antigen, hepatitis C virus antibody, and rapid plasma re- agin; and a negative HIV-1 enzyme-linked immunosorbent assay (ELISA). Exclusion criteria included the contraindications against vaccination noted in the package insert (pregnancy, immunosup- pression, and eczema), a history of vaccination with live attenu- ated virus within 60 days before the study, the receipt of blood products or immune globulin within 6 months before the study, and household contact, sexual contact, or occupational exposure to pregnant women, immunosuppressed persons, persons with ecze- ma, or infants less than 12 months of age.

A total of 60 subjects were enrolled and were randomly as- signed to receive undiluted vaccine, a 1:10 dilution of vaccine, or a 1:100 dilution of vaccine. Twenty subjects were enrolled in each group. Group assignment was revealed to the subjects after day 45. Laboratory personnel remained unaware of treatment assign- ments until all assays were completed. Subjects were inoculated by scarification: a bifurcated needle that held a drop of vaccine was

isolated and cultured on continuous African-green-monkey

Isolation of Virus and Antibody Assays

Swab samples of each lesion were obtained on day 7, 8, or 9 after vaccination; the end point was a 60-percent reduction in the number of plagues as described previously.¹¹ Serum binding anti- body levels were measured by ELISA as described previously.¹² Vaccinia virus antigen and serum samples to be used as positive and negative controls were provided by Dr. George Ludwig (U.S. Army Medical Research Institute of Infectious Diseases, Fort De- trick, Md.).

Cytotoxicity Assays

Cryopreserved peripheral-blood mononuclear cells obtained from all subjects on day 0 and at six months were thawed and test- ed in the same assay. Target cells were autologous Epstein–Barr vi- rus–transformed lymphoblastoid cells that had been infected with vaccinia virus one day earlier and that were labeled with chromi- um-51 on the day of the assay.¹³ Effector cells were exposed to virus-infected autologous peripheral-blood mononuclear cells for six days at 37°C and then added at various effector-to-target ratios (10:1, 30:1, and 90:1) in 96-well U-bottom plates, in triplicate, for 4.5 hours as described previously.¹⁴ At each effector–target ratio, vaccinia-specific immune lysis was calculated as the difference be- tween the percent lysis of infected targets and the percent lysis of uninfected targets. The number of effector cells required to lyse 30 percent of target cells (referred to as lytic units) per million cells was determined by an exponential-fit method with the use of commer- cial software (Proteins International, Rochester Hills, Mich.).

Interferon-γ Assays

A modified enzyme-linked immunosorbt assay was used to de- tect live virus-specific release of interferon-γ by cryopreserved pe- ripheral-blood mononuclear cells as previously described,¹⁵ except that stock vaccinia virus was used to stimulate peripheral-blood mononuclear cells at a multiplicity of infection of 1.0 pfu per cell. The frequency of interferon-γ–positive T cells specific for vaccinia virus per million peripheral-blood mononuclear cells was de- termined, and the results were considered positive if the number of spots per million peripheral-blood mononuclear cells in virus- stimulated wells was twice as high as the number of spots per mil- lion cells in the control wells and if at least 20 spots per million peripheral-blood mononuclear cells were present. Preliminary studies (Ennis FA: unpublished data) indicated that most of the T cells that release vaccinia virus–specific interferon-γ are CD8+.

Proliferation Assays

Proliferation assays were performed in replicates of five as de- scribed previously.¹⁶ For each group of five replicates, the stimu- lation index was calculated as the mean of the three intermediate values (expressed as counts per minute).

Statistical Analysis

The objective of this study was to assess the effects of diluted vaccinia virus vaccine on clinical and laboratory indicators of pro- tective immunity. To be considered successful, a given dilution had to evoke a response in at least 18 of the 20 subjects in a group (a success rate of 90 percent). Thus, a sample size of 20 involved an 8 percent chance of rejecting a vaccine with a 95 percent suc- cess rate and a 32 percent chance of rejecting a marginally accept- able vaccine with a 90 percent success rate. A sample size of 20 was selected on the basis of these considerations and the under- standing that the selection of a dilution will not depend solely on the dichotomous measure of success or failure in any group. Pairs of success rates were compared with use of standard asymptotic methods for binomial comparisons, and all three groups were com- pared with use of the Kruskal–Wallis test for trend.¹³ T-cell responses were analyzed by analysis of variance with the use of SPSS statistical software (SPSS, Chicago). Multiple post hoc
comparisons of the study groups were made with the use of the Tukey adjustment for multiplicity. All $t$-tests were two-sided.

RESULTS

Clinical Findings

Of the 60 subjects, 2 had a fever (temperature, up to 39°C [102.2°F]) for 1 or 2 days beginning 11 and 12 days, respectively, after vaccination. One subject reported a stiff neck on days 12 and 13 after vaccination. One subject reported intermittent dizziness, floaters, and tachycardia starting on day 15 after vaccination and lasting two weeks. One subject had an intermittent rash on the arms and legs and muscle aches on days 9 through 13. Two subjects had an elevated alanine aminotransferase level ($\approx 84$ U per liter) on day 28; the elevation resolved two weeks later in one subject and was still present at the time of the last follow-up visit in the other. One subject had a transient, mild decrease in the hemoglobin level (13.4 to 11.7 g per deciliter) on day 28. On urinalysis at six months, one subject transiently had 11 white cells per high-power field. Three subjects reported that the skin around the dressing was irritated. One subject in whom vaccination failed reported myalgias and pain at the vaccination site seven days after vaccination. There were no serious adverse events. One subject who received the 1:100 dilution of vaccine withdrew after vaccination for reasons unrelated to the study. Fifty-five of the subjects provided blood specimens at one year, as planned.

Success Rates

Vaccination success rates — defined by the formation of a vesicle at the inoculation site seven to nine days after vaccination — were dose-dependent ($P<0.001$ by the Kruskal–Wallis test): vaccination was successful in 19 of 20 subjects who received undiluted vaccine (mean viral titer, $10^{7.8}$ pfu per milliliter; range, $10^{7.4}$ to $10^{8.3}$), 14 of 20 who received a 1:10 dilution (mean viral titer, $10^{6.5}$ pfu per milliliter; range, $10^{6.1}$ to $10^{7.0}$), and 3 of 20 who received a 1:100 dilution (mean viral titer, $10^{5.0}$ pfu per milliliter; range, $10^{4.2}$ to $10^{5.9}$). The success rate was significantly lower in the group that received the 1:10 dilution than in the group that received the undiluted vaccine (70 percent vs. 95 percent; absolute difference, 25 percent; 95 percent confidence interval for the difference, 3 to 47 percent; $P=0.03$ with the use of asymptotic methods). Once viral infection of the skin was initiated, the resulting lesion was approximately 1 cm in diameter, regardless of the dose of vaccine. Vaccinia virus was isolated from swab samples of skin lesions in 35 of the 36 subjects with vesicles.
Antibody Responses

Among 36 subjects with vesicles, neutralizing antibody titers and antibody titers on ELISA increased by a factor of at least 4 at one month in 34 and 26 subjects, respectively (Table 1). In the 33 subjects with vesicles who returned for follow-up at one year, neutralization titers at one year averaged 23.7 percent of the titers on day 28 (95 percent confidence interval, 7 to 33 percent) and ELISA titers averaged 64.3 percent of the titers on day 28 (95 percent confidence interval, 44.8 to 96.6 percent) (Table 1).

Cytotoxic T-Cell and Interferon-γ Responses

The development of a vesicle correlated with the development of cytotoxic T-cell responses in 31 of 32 subjects (of 4 other subjects with vesicles, 2 had nonviable cells and 2 had a high background response on the cytotoxic T-cell assay) and an increase in the number of T cells positive for virus-specific interferon-γ by enzyme-linked immunospot assay in 31 of 34 subjects. Figure 2A demonstrates vaccinia virus-specific cytotoxic T-cell activity six months after scarification with undiluted vaccine, the 1:10 dilution of vaccine, and the 1:100 dilution of vaccine. When the magnitude of the cytotoxic T-cell responses was based on the percent lysis among subjects with vesicle formation in each group, there was no significant difference between the group given undiluted vaccine and the group given the 1:10 dilution (P=0.052), but the difference between the group given undiluted vaccine and the group given the 1:100 dilution was significant (P<0.001). None of the subjects had vaccinia virus–specific cytotoxic T-cell activity on day 0 (before vaccination). One subject in the group given the 1:100 dilution did not have a vaccinial skin lesion but did have a virus-specific cytotoxic T-cell response after vaccination (Fig. 2A).

Enzyme-linked immunospot assays were used to determine the number of cells that produced vaccinia virus–specific interferon-γ in peripheral-blood mononuclear cells obtained before and six months after vaccination. As shown in Figure 2B, the numbers were significantly different among the three groups. The presence of cells producing vaccinia virus–specific interferon-γ correlated with the development of both a vesicle and a cytotoxic T-cell response. One subject who received the 1:100 dilution had a positive enzyme-linked immunospot assay and a cytotoxic T-cell response but did not have a skin response to the vaccine. Three subjects with vesicle formation did not have a positive enzyme-linked immunospot assay. In subjects with vesicle formation, the magnitude of the interferon-γ response was significantly lower among those given the 1:10 dilution of vaccine or the 1:100 dilution than among those given the undiluted vaccine (P=0.038 and P<0.001, respectively).

Lymphocyte Proliferation

Lymphocyte proliferation was induced in response to vaccinia virus in 33 of 34 subjects with vesicle formation and in none of 23 subjects without vesicle formation (Fig. 2C). There were no significant dose-related differences in the stimulation index at six months among subjects with vesicle formation, al-
though there were significant overall dose–response differences in the stimulation index between the group given undiluted vaccine and the group given the 1:100 dilution (P=0.039), because of the higher frequency of nonresponse in the latter group. Examination of peripheral-blood mononuclear cells obtained before vaccination indicated that none of the subjects had had previous exposure to the virus (data not shown).

**DISCUSSION**

Immunization with vaccinia virus remains the only available option for protection against smallpox infection. The current supply of vaccine is viable and has a good titer, but dilution of the vaccine to titers of less than $10^7$ pfu per milliliter reduced the rates of successful vaccination. Serial dilution of the vaccine stock resulted in nonlinear reductions in the titer (e.g., a 1:100 dilution reduced the titer from $10^{7.8}$ pfu per milliliter to $10^{5.0}$ pfu per milliliter). This effect may result from the highly viscous nature of the preparation. As compared with the 95 percent rate of success associated with the undiluted vaccine, the rate of success associated with the dose of $10^{6.5}$ pfu per milliliter provided by the 1:10 dilution was 70 percent. This lower rate is similar to the 75 percent rate reported among children who were vaccinated with a similar vaccine and dose ($10^7$ pock-forming units per milliliter). The dose of $10^{6.5}$ pfu per milliliter provided by the 1:10 dilution was associated with a success rate of only 15 percent. These results indicate that serial dilution of the current vaccine to less than $10^{6.5}$ pfu per milliliter results in a loss of potency ($P=0.001$ for the comparison of undiluted vaccine with a 1:10 dilution alone and $P<0.001$ for the comparison of undiluted vaccine with both dilutions of vaccine).

There was a dose–response effect: higher doses produced significantly stronger cytotoxic T-cell and interferon-γ responses. Given the small number of subjects in whom vaccination with a 1:10 or 1:100 dilution was successful, additional study is needed to confirm these observations. Findings in vaccinated children and adults with T-cell–related immunodeficiencies indicate that T-cell responses are a critical element in the recovery from pox virus infections.

The cytotoxic T-cell and interferon-γ responses in our study were much stronger than those reported after the receipt of experimental HIV-1 vaccines and cor-
we used.\textsuperscript{19,22} We found that the absence of primary skin vesicles after the administration of diluted vaccine was associated with the absence of vaccinia virus–specific T-cell and B-cell responses and antibody in protecting against pox viruses, such as variola.\textsuperscript{21} In our study, the induction of vaccinia virus–specific T-cell and B-cell responses was associated with clinically observable pox lesions. Previous studies have shown that the response is attenuated if the route of administration differs from the one that we used.\textsuperscript{19,22} We found that the absence of primary skin vesicles after the administration of diluted vaccine was associated with the absence of vaccinia virus–specific T-cell or B-cell responses and is therefore likely to indicate the absence of protective immunity. Future studies are needed to assess the effectiveness of vaccine titers of $10^6.5$ to $10^8.0$ pfu per milliliter in both previously vaccinated and unvaccinated populations. Evaluation of new cell-culture–derived vaccines should address both T-cell and B-cell responses. If vaccinations with dilutions of the current vaccine are administered, revaccination should be considered in persons without vesicle formation.

Diluting the available vaccine to titers of $10^{6.5}$ per milliliter or less reduced the frequency rates of local viral replication and vesicle formation — effects that are essential stimuli for protective immune responses, as evidenced by the lack of antibody, cytoxic T-cell, and interferon-\(\gamma\) responses. Previous reports in which smallpox vaccination in patients with defects in either cellular or humoral immunity led to severe vaccinia underscore the essential role of T-cell responses and antibody in protecting against pox viruses, such as variola.\textsuperscript{21} We are indebted to James Meegan, Wendy Fanaroff-Ravick, and Catherine Laughlin at the National Institute of Allergy and Infectious Diseases, Bethesda, Md., and John Becher at the CDC for their assistance and thoughtful discussions, to Ruth Mazzeo for performing the proliferation assays, and to the staff at the Saint Louis University Vaccine and Treatment Evaluation Unit.


Copyright © 2002 Massachusetts Medical Society.


\textsuperscript{5} Russell PK. Vaccines in civilian defense against bioterrorism. Emerg Infect Dis 1999;5:581-3.


\textsuperscript{17} McClain DJ, Harrison S, Yeager CL, et al. Immunologic responses to vaccinia vaccines administered by different parenteral routes. J Infect Dis 1997;175:756-63.


Copyright © 2002 Massachusetts Medical Society.